AACR Annual Meeting | Conference

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors

April 11th 2022

The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.

ZD5305 Proves Favorable to First-Generation PARP Inhibitors Across Different Cancer Types

April 11th 2022

AZD5305, a next generation PARP inhibitor, produced favorable safety and clinical activity vs first-generation PARP inhibitors in patients with multiple different cancer types.

Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC

April 11th 2022

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC

April 11th 2022

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.

Pembrolizumab Plus Chemotherapy Elicits Meaningful pCR for Gastric, GEJ Adenocarcinoma

April 11th 2022

Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Pepinemab Plus Pembrolizumab Promotes Antitumor Activity in Recurrent/Metastatic Head and Neck Cancer

April 11th 2022

The combination of pepinemab and pembrolizumab elicited encouraging responses and tolerability as frontline therapy in patients with recurrent or metastatic head and neck cancer.

Genetically Adjusting PSA May Improve Screening with PSA Alone in Prostate Cancer

April 11th 2022

The genetic adjustment of prostate-specific antigen could reduce over-diagnosis, de-escalate invasive testing, and improve the detection of aggressive disease in patients with prostate cancer.

YAP1, Inflamed T-Cell Subtypes Linked With Improved Durvalumab/ Chemo Responses in ES-SCLC

April 11th 2022

Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Nivolumab/Chemotherapy Generate Survival Benefit Vs Chemotherapy Alone in Gastric Cancer, Regardless of TMB

April 11th 2022

The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11th 2022

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

Nivolumab/Ipilimumab Produces Promising ORR in Advanced tTMB- and bTMB-High Solid Tumors

April 11th 2022

The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.

Elimusertib Elicits Responses in Solid Tumors With ATM Alterations and BRCA Mutations

April 11th 2022

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL

April 10th 2022

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

Dr. Elemento on Utilizing Circulating Tumor Cells to Assess Treatment Resistance in mCRPC

April 10th 2022

Olivier Elemento, PhD, discusses utilizing circulating tumor cells to assess treatment resistance in metastatic castration-resistant prostate cancer.

GD2-Directed CAR T-Cell Therapy Elicits Durable Benefit in H3K27M-Mutated Diffuse Intrinsic Pontine Gliomas

April 10th 2022

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

April 10th 2022

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Off-the-Shelf Anti-Mesothelin CAR T-cell Therapy Improves In Vivo Activity Vs Gavo-Cel in Mesothelin-Expressing Tumors

April 10th 2022

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell Therapy

April 10th 2022

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBC

April 10th 2022

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.